I Prosser

829 total citations
18 papers, 632 citations indexed

About

I Prosser is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, I Prosser has authored 18 papers receiving a total of 632 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 8 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in I Prosser's work include Multiple Myeloma Research and Treatments (7 papers), Acute Myeloid Leukemia Research (3 papers) and Peptidase Inhibition and Analysis (3 papers). I Prosser is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Acute Myeloid Leukemia Research (3 papers) and Peptidase Inhibition and Analysis (3 papers). I Prosser collaborates with scholars based in Australia, United States and Switzerland. I Prosser's co-authors include Robert P. Mecham, William C. Parks, Andrew Spencer, Ed Crouch, Kurt R. Stenmark, Manish Suthar, H. Miles Prince, Noemi Horvath, Kenneth F. Bradstock and Andrew W. Roberts and has published in prestigious journals such as Journal of Clinical Oncology, Blood and BJOG An International Journal of Obstetrics & Gynaecology.

In The Last Decade

I Prosser

16 papers receiving 615 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
I Prosser Australia 10 359 322 234 89 78 18 632
Cristina Panaroni United States 14 248 0.7× 377 1.2× 231 1.0× 106 1.2× 102 1.3× 31 908
Stefan Gröschel Germany 14 303 0.8× 319 1.0× 162 0.7× 136 1.5× 86 1.1× 25 712
Gabriella Sammarelli Italy 16 465 1.3× 404 1.3× 438 1.9× 174 2.0× 109 1.4× 39 938
TS Ganesan United Kingdom 14 215 0.6× 319 1.0× 149 0.6× 91 1.0× 75 1.0× 23 942
Takehide Akiyama Japan 10 446 1.2× 263 0.8× 272 1.2× 75 0.8× 68 0.9× 28 825
Philippe Hénon France 17 415 1.2× 255 0.8× 199 0.9× 43 0.5× 41 0.5× 56 808
Claudine Graf Germany 15 126 0.4× 166 0.5× 209 0.9× 88 1.0× 52 0.7× 26 545
Sigal Tavor Israel 17 653 1.8× 528 1.6× 471 2.0× 49 0.6× 121 1.6× 33 1.3k
T M Dexter United Kingdom 15 399 1.1× 225 0.7× 205 0.9× 70 0.8× 40 0.5× 24 822
Shingo Wakatsuki Japan 11 203 0.6× 213 0.7× 289 1.2× 70 0.8× 29 0.4× 29 657

Countries citing papers authored by I Prosser

Since Specialization
Citations

This map shows the geographic impact of I Prosser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I Prosser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I Prosser more than expected).

Fields of papers citing papers by I Prosser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I Prosser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I Prosser. The network helps show where I Prosser may publish in the future.

Co-authorship network of co-authors of I Prosser

This figure shows the co-authorship network connecting the top 25 collaborators of I Prosser. A scholar is included among the top collaborators of I Prosser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I Prosser. I Prosser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Hapgood, Greg, Janey M. Stone, Diana Zannino, et al.. (2018). A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. Leukemia & lymphoma. 60(4). 904–911. 8 indexed citations
2.
Bradstock, Kenneth F., Alec Morley, Karen Byth, et al.. (2016). Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia. Contemporary Clinical Trials Communications. 4. 9–13. 1 indexed citations
3.
4.
Talaulikar, Dipti, et al.. (2010). Novel therapeutic option for orbital atypical lymphoid hyperplasia. Clinical and Experimental Ophthalmology. 38(9). 892–894. 4 indexed citations
5.
Miguel, Jesús F. San, Andreas Güenther, Joan Bladé, et al.. (2010). Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).. Journal of Clinical Oncology. 28(15_suppl). 8001–8001. 8 indexed citations
6.
Siegel, David S., Jesús F. San Miguel, MV Mateos, et al.. (2009). A337 Panobinostat and Bortezomib Phase I Trial in Multiple Myeloma. Clinical Lymphoma & Myeloma. 9. S54–S54. 2 indexed citations
7.
Kenealy, Melita, John F. Seymour, Alvin Milner, et al.. (2009). The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).. Blood. 114(22). 1749–1749. 2 indexed citations
8.
Spencer, Andrew, H. Miles Prince, Andrew W. Roberts, et al.. (2009). Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure. Journal of Clinical Oncology. 27(11). 1788–1793. 227 indexed citations
9.
Miguel, Jesús F. San, Orhan Sezer, David S. Siegel, et al.. (2009). A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.. Blood. 114(22). 3852–3852. 11 indexed citations
10.
Sezer, Orhan, Jesús F. San Miguel, María‐Victoria Mateos, et al.. (2008). A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma. Blood. 112(11). 2781–2781. 37 indexed citations
11.
12.
Spencer, Andrew, Noemi Horvath, John Gibson, et al.. (2005). Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation. 35(10). 971–977. 55 indexed citations
13.
14.
Peek, Michael, et al.. (2002). Is there an increased maternal–infant prevalence of Factor V Leiden in association with severe pre‐eclampsia?. BJOG An International Journal of Obstetrics & Gynaecology. 109(2). 191–196. 40 indexed citations
15.
Prosser, I. (1998). [On the distribution of body hair in persons with prostatic hypertrophy].. PubMed. 12. 115–8.
16.
Prosser, I. (1998). [ABO blood groups in hypertrophy of the prostate].. PubMed. 11. 253–5.
17.
Prosser, I, William C. Parks, Mona Ståhle‐Bäckdahl, et al.. (1991). Polyclonal antibodies to tropoelastin and the specific detection and measurement of tropoelastinin vitro. Connective Tissue Research. 25(3-4). 265–279. 30 indexed citations
18.
Prosser, I, Kurt R. Stenmark, Manish Suthar, et al.. (1989). Regional heterogeneity of elastin and collagen gene expression in intralobar arteries in response to hypoxic pulmonary hypertension as demonstrated by in situ hybridization.. PubMed. 135(6). 1073–88. 167 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cristina Panaroni Breakdown of academic impact, for papers by Stefan Gröschel Breakdown of academic impact, for papers by Gabriella Sammarelli Breakdown of academic impact, for papers by TS Ganesan Breakdown of academic impact, for papers by Takehide Akiyama Breakdown of academic impact, for papers by Philippe Hénon Breakdown of academic impact, for papers by Claudine Graf Breakdown of academic impact, for papers by Sigal Tavor Breakdown of academic impact, for papers by T M Dexter Breakdown of academic impact, for papers by Shingo Wakatsuki
Rankless by CCL
2026